Efficacy and Safety of Anlotinib and PD-1/L1 Inhibitors as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer Patients who Have Achieved Stable-Disease After First-Line Treatment with Chemotherapy and Immunotherapy: A Retrospective Study
Objective To develop personalized treatment strategies for maintenance therapy in patients with extensive-stage small cell lung cancer (ES-SCLC). Materials and Methods We analyzed data from ES-SCLC patients who achieved stable disease (SD) following initial chemotherapy combined with immunotherapy....
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
SAGE Publishing
2025-01-01
|
| Series: | Cancer Control |
| Online Access: | https://doi.org/10.1177/10732748251318383 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832539954850299904 |
|---|---|
| author | Yi Peng MD De Wu MD Jing Tang MD Xiaobing Li MD |
| author_facet | Yi Peng MD De Wu MD Jing Tang MD Xiaobing Li MD |
| author_sort | Yi Peng MD |
| collection | DOAJ |
| description | Objective To develop personalized treatment strategies for maintenance therapy in patients with extensive-stage small cell lung cancer (ES-SCLC). Materials and Methods We analyzed data from ES-SCLC patients who achieved stable disease (SD) following initial chemotherapy combined with immunotherapy. These patients subsequently received maintenance therapy (MT) with a combination of anlotinib and PD-1/L1 inhibitors. The primary endpoints included progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and treatment-related adverse events (AEs). Results Preliminary findings suggest that this regimen is highly effective, with a median PFS of 6 months and OS of 13.5 months, alongside a DCR exceeding 60%. Subgroup analysis revealed enhanced efficacy in patients with fewer than three metastatic sites and those who experienced hypertension, proteinuria, or hand-foot syndrome during MT. Mechanistic studies showed a notable increase in the proportion of CD8+ T cells in the peripheral blood post-MT, correlating with improved outcomes. These findings imply that the therapeutic effect of MT may be partly due to the direct activation of CD8+ T cells, producing a synergistic anti-tumor response. Despite the prevalence of AEs, AEs were generally manageable, underscoring anlotinib’s potential in this context. Conclusion The combination of anlotinib and PD-1/L1 inhibitors offers promising efficacy and manageable AEs in MT, making it a viable option for ES-SCLC patients who achieve SD post-initial therapy. These results justify further prospective studies to validate this approach. |
| format | Article |
| id | doaj-art-2bd4511be78d4fafbc2fbefddf517ef0 |
| institution | Kabale University |
| issn | 1526-2359 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | SAGE Publishing |
| record_format | Article |
| series | Cancer Control |
| spelling | doaj-art-2bd4511be78d4fafbc2fbefddf517ef02025-02-05T07:03:25ZengSAGE PublishingCancer Control1526-23592025-01-013210.1177/10732748251318383Efficacy and Safety of Anlotinib and PD-1/L1 Inhibitors as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer Patients who Have Achieved Stable-Disease After First-Line Treatment with Chemotherapy and Immunotherapy: A Retrospective StudyYi Peng MDDe Wu MDJing Tang MDXiaobing Li MDObjective To develop personalized treatment strategies for maintenance therapy in patients with extensive-stage small cell lung cancer (ES-SCLC). Materials and Methods We analyzed data from ES-SCLC patients who achieved stable disease (SD) following initial chemotherapy combined with immunotherapy. These patients subsequently received maintenance therapy (MT) with a combination of anlotinib and PD-1/L1 inhibitors. The primary endpoints included progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and treatment-related adverse events (AEs). Results Preliminary findings suggest that this regimen is highly effective, with a median PFS of 6 months and OS of 13.5 months, alongside a DCR exceeding 60%. Subgroup analysis revealed enhanced efficacy in patients with fewer than three metastatic sites and those who experienced hypertension, proteinuria, or hand-foot syndrome during MT. Mechanistic studies showed a notable increase in the proportion of CD8+ T cells in the peripheral blood post-MT, correlating with improved outcomes. These findings imply that the therapeutic effect of MT may be partly due to the direct activation of CD8+ T cells, producing a synergistic anti-tumor response. Despite the prevalence of AEs, AEs were generally manageable, underscoring anlotinib’s potential in this context. Conclusion The combination of anlotinib and PD-1/L1 inhibitors offers promising efficacy and manageable AEs in MT, making it a viable option for ES-SCLC patients who achieve SD post-initial therapy. These results justify further prospective studies to validate this approach.https://doi.org/10.1177/10732748251318383 |
| spellingShingle | Yi Peng MD De Wu MD Jing Tang MD Xiaobing Li MD Efficacy and Safety of Anlotinib and PD-1/L1 Inhibitors as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer Patients who Have Achieved Stable-Disease After First-Line Treatment with Chemotherapy and Immunotherapy: A Retrospective Study Cancer Control |
| title | Efficacy and Safety of Anlotinib and PD-1/L1 Inhibitors as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer Patients who Have Achieved Stable-Disease After First-Line Treatment with Chemotherapy and Immunotherapy: A Retrospective Study |
| title_full | Efficacy and Safety of Anlotinib and PD-1/L1 Inhibitors as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer Patients who Have Achieved Stable-Disease After First-Line Treatment with Chemotherapy and Immunotherapy: A Retrospective Study |
| title_fullStr | Efficacy and Safety of Anlotinib and PD-1/L1 Inhibitors as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer Patients who Have Achieved Stable-Disease After First-Line Treatment with Chemotherapy and Immunotherapy: A Retrospective Study |
| title_full_unstemmed | Efficacy and Safety of Anlotinib and PD-1/L1 Inhibitors as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer Patients who Have Achieved Stable-Disease After First-Line Treatment with Chemotherapy and Immunotherapy: A Retrospective Study |
| title_short | Efficacy and Safety of Anlotinib and PD-1/L1 Inhibitors as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer Patients who Have Achieved Stable-Disease After First-Line Treatment with Chemotherapy and Immunotherapy: A Retrospective Study |
| title_sort | efficacy and safety of anlotinib and pd 1 l1 inhibitors as maintenance therapy for extensive stage small cell lung cancer patients who have achieved stable disease after first line treatment with chemotherapy and immunotherapy a retrospective study |
| url | https://doi.org/10.1177/10732748251318383 |
| work_keys_str_mv | AT yipengmd efficacyandsafetyofanlotinibandpd1l1inhibitorsasmaintenancetherapyforextensivestagesmallcelllungcancerpatientswhohaveachievedstablediseaseafterfirstlinetreatmentwithchemotherapyandimmunotherapyaretrospectivestudy AT dewumd efficacyandsafetyofanlotinibandpd1l1inhibitorsasmaintenancetherapyforextensivestagesmallcelllungcancerpatientswhohaveachievedstablediseaseafterfirstlinetreatmentwithchemotherapyandimmunotherapyaretrospectivestudy AT jingtangmd efficacyandsafetyofanlotinibandpd1l1inhibitorsasmaintenancetherapyforextensivestagesmallcelllungcancerpatientswhohaveachievedstablediseaseafterfirstlinetreatmentwithchemotherapyandimmunotherapyaretrospectivestudy AT xiaobinglimd efficacyandsafetyofanlotinibandpd1l1inhibitorsasmaintenancetherapyforextensivestagesmallcelllungcancerpatientswhohaveachievedstablediseaseafterfirstlinetreatmentwithchemotherapyandimmunotherapyaretrospectivestudy |